Clinical trial · Interventional
Double Filtration Plasmapheresis Combined With Chemotherapy
Clinical Research of Double Filtration Plasmapheresis Combined With Chemotherapy to Remove M Protein in Multiple Myeloma
NCT04836871CI-TRIAL-00067979unknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluation of double filtration plasmapheresis combined with chemotherapy for the treatment of abnormalities of M protein or renal function due to the multiple myeloma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DFPP combined with chemotherapy | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Double filtration plasmapheresis (DFPP) combined with chemotherapy
- interventionNames
- Combination Product: DFPP combined with chemotherapy
Primary outcomes (12)
- measure
- M protein clearance rate
- timeFrame
- 1hour
- description
- before each treatment of Double filtration plasmapheresis (DFPP)
- measure
- M protein clearance rate
- timeFrame
- 1hour
- description
- after each treatment of DFPP
- measure
- creatinine clearance rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Multiple myeloma patients who are diagnosed by bone marrow morphology and immunology * Patients with stable condition after conventional treatment * Patients with renal insufficiency or abnormal M protein * Patients over 18 years of age * Liver function: blood bilirubin ≤ 35μmol/L, enzymes aspartate transaminase (AST)/aka alanine aminotransferase (ALT) is less than 2 times the upper limit of normal * Normal heart function * Physical condition score 0-2 level (ECOG score) * Obtain an informed consent form signed by the patient or family member Exclusion Criteria: * Allergies or obvious contraindications to any of the drugs involved in the plan * Severe heart disease, including myocardial infarction and cardiac insufficiency. * Suffering from other organ malignancies * Active tuberculosis patients and HIV-positive patients * At the same time suffering from other blood system diseases * Pregnant or lactating women * Able to understand or follow the research plan * Past history of intolerance or allergy to similar drugs * Patients under 18 years of age * Participating in other clinical researchers at the same time * There are any other circumstances that hinder the progress of the research
References
Publications (0)
Data not yet available
No reference posted for this study.